TD Waterhouse Canada Inc. Decreases Stock Holdings in Danaher Corporation $DHR

TD Waterhouse Canada Inc. lowered its position in shares of Danaher Corporation (NYSE:DHR) by 15.5% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 66,227 shares of the conglomerate’s stock after selling 12,166 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Danaher were worth $14,134,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in DHR. WFA of San Diego LLC purchased a new stake in shares of Danaher during the second quarter worth about $26,000. Howard Hughes Medical Institute bought a new position in Danaher during the 2nd quarter valued at approximately $27,000. TruNorth Capital Management LLC bought a new position in Danaher during the 3rd quarter valued at approximately $28,000. Red Tortoise LLC grew its position in shares of Danaher by 175.0% in the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock worth $30,000 after buying an additional 98 shares during the last quarter. Finally, Tripletail Wealth Management LLC bought a new stake in shares of Danaher in the 3rd quarter worth approximately $31,000. Institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Argus set a $265.00 price target on Danaher in a research note on Wednesday, January 14th. JPMorgan Chase & Co. upped their price objective on shares of Danaher from $270.00 to $275.00 and gave the stock an “overweight” rating in a report on Thursday. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Robert W. Baird set a $251.00 price target on shares of Danaher in a research report on Thursday. Finally, TD Cowen restated a “buy” rating on shares of Danaher in a report on Wednesday, January 7th. Twenty research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $252.55.

Danaher Trading Down 2.2%

Shares of NYSE DHR opened at $219.62 on Friday. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $242.80. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.87 and a quick ratio of 1.10. The firm has a 50-day moving average of $230.77 and a 200 day moving average of $213.81. The stock has a market cap of $155.13 billion, a P/E ratio of 43.58, a price-to-earnings-growth ratio of 3.42 and a beta of 0.89.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 28th. The conglomerate reported $2.23 earnings per share for the quarter, topping analysts’ consensus estimates of $2.14 by $0.09. Danaher had a net margin of 14.71% and a return on equity of 10.81%. The business had revenue of $6.84 billion for the quarter, compared to analysts’ expectations of $6.79 billion. During the same quarter in the prior year, the company earned $2.14 earnings per share. The business’s revenue was up 4.6% compared to the same quarter last year. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. As a group, sell-side analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, December 26th. Danaher’s dividend payout ratio (DPR) is 26.39%.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher beat Q4 consensus — reported $2.23 EPS vs. ~$2.14 expected and revenue $6.84B topping estimates, showing growth across Life Sciences, Diagnostics and Bioprocessing. PR Newswire: Q4 Results
• Positive Sentiment: Analyst support: JPMorgan raised its price target to $275 and kept an Overweight rating, highlighting upside vs. current levels and supporting longer‑term conviction. Benzinga: JPMorgan PT Raise
• Neutral Sentiment: FY‑2026 EPS guidance of $8.35–$8.50 was issued and sits essentially inline with the Street (~$8.42), so the outlook is credible but not a positive catalyst above expectations. Reuters: 2026 Forecast
• Neutral Sentiment: Management highlighted strong free cash flow and balance‑sheet strength, which supports buybacks/dividends and long‑term investment in bioprocessing but is not a near‑term growth surprise. TipRanks: Cash Strength
• Negative Sentiment: Market reaction: shares fell after the print as investors parsed the in‑line guidance and cautious commentary on end‑market recovery, leading to short‑term selling despite the beat. Seeking Alpha: Stock Drops
• Negative Sentiment: Commentary emphasized a gradual (not rapid) recovery in pharma spending and continued weakness in some academic research markets — investors looking for a stronger acceleration may have reduced exposure. Benzinga: Gradual Improvement

Insider Buying and Selling at Danaher

In other Danaher news, Director Teri List sold 3,298 shares of the business’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total value of $746,997.00. Following the sale, the director directly owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. The trade was a 13.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the transaction, the senior vice president owned 14,553 shares of the company’s stock, valued at $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 30,248 shares of company stock worth $6,609,663. 11.10% of the stock is owned by insiders.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.